A Randomized, Double-blind, Placebo-controlled, Pharmacokinetic, Safety and Tolerability, and Exploratory Efficacy and Pharmacodynamic Effects Study of RO4917523 in Adult Patients With Fragile X Syndrome.
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2016
At a glance
- Drugs Basimglurant (Primary)
- Indications Behavioural symptoms; Cognition disorders; Fragile X syndrome
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Roche
- 23 May 2013 Actual initiation date changed from Sep 2011 to Jan 2011 as reported by ClinicalTrials.gov.
- 09 Nov 2011 New trial record